Abstract:Simple Summary The prognosis of patients with primary central nervous system lymphoma (PCNSL) is poor due to the high recurrence rate and lack of consensus on the optimal treatment for refractory or relapsed diseases. Despite having good prognostic scores, such as an MSKCC score or IELSG score, none of them are able to fully explain the clinical outcomes of patients with PCNSL, and they are complicated at the same time. Thus, there is an urgent need to develop simple and readily available parameters that help to stratify the prognosis of patients, especially those at high risk, and provide them with appropriate treatment measures. For the first time, this study identified that pretreatment serum total bilirubin (STB) could predict the prognosis of patients with PCNSL receiving high-dose methotrexate-based combination immunochemotherapy. The results from this study demonstrate that STB is a simple, cost-effective prognostic biomarker that clinicians can apply easily and quickly into routine practice. Abstract Primary central nervous system lymphoma (PCNSL) is a predominantly aggressive neoplasm isolated to the central nervous system or vitreoretinal space. Bilirubin is an important biomarker reflecting hepatic function and oxidative stress status that is associated with the occurrence and development of various tumors. However, its prognostic role in PCNSL has yet to be evaluated. Therefore, we conducted a prospective–retrospective study to analyze the predictive value of serum total bilirubin (STB) in PCNSL patients. The association between the pretreatment STB and clinical outcomes in PCNSL was developed in the discovery cohort (retrospective [n = 44] and prospective [n = 45]) and validated in an independent retrospective cohort (n = 69). A generalized additive model, Kaplan–Meier curve, and Cox analysis were applied. In the discovery cohort, the STB showed a linear relationship with overall survival (OS, p = 0.011) and progression-free survival (PFS, p = 0.0476). The median STB level of 12.0 µmol/L was determined as the cutoff value to predict the clinical outcomes with area under the receiver operating characteristic curve (AUROC) values of 0.9205 and 0.8464 for OS and PFS, respectively. The median STB level resulted in similar accuracy for predicting the clinical outcomes in the validation cohort with AUROC values of 0.8857 and 0.8589 for OS and PFS, respectively. In both the discovery and validation cohorts, the Kaplan–Meier survival curve and Cox regression analysis showed that the upper median STB groups showed significantly worse OS than the lower median STB groups. In conclusion, the pretreatment STB could be considered a novel biomarker to predict the clinical outcomes in patients with PCNSL receiving high-dose methotrexate-based combination immunochemotherapy.

Association of total bilirubin and prognosis in disorders of consciousness

Peripheral Inflammatory Markers in Patients with Prolonged Disorder of Consciousness after Severe Traumatic Brain Injury.

Effects of Bilirubin on Perioperative Myocardial Infarction and Its Long-Term Prognosis in Patients Undergoing Percutaneous Coronary Intervention

Association of direct bilirubin to total bilirubin ratio with 90-day mortality in patients with acute-on-chronic liver failure

Serum bilirubin level correlates with mortality in patients with traumatic brain injury.

Serum Bilirubin Associated with Stroke Severity and Prognosis: Preliminary Findings on Liver Function after Acute Ischemic Stroke

Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19

Elevated Serum Total Bilirubin Level is Associated with Poor Outcomes in Pediatric Patients with Sepsis-Associated Liver Injury

Association of Serum Bilirubin with Stroke Severity and Clinical Outcomes

Serum Total Bilirubin With Hospital Survival in Adults During Extracorporeal Membrane Oxygenation

Relation of Direct, Indirect, and Total bilirubin to Adverse Long-term Outcomes Among Patients With Acute Coronary Syndrome.

The Correlation Between Serum Total Bilirubin and Outcomes in Patients with Different Subtypes of Coronary Artery Disease

The impact of serum total bilirubin level on long-term prognosis in patients with chronic heart failure]

Direct Bilirubin Levels Predict Long-Term Outcomes in Patients With Acute Coronary Syndrome Under Different Glucose Metabolism Status: A 6.5-Year Cohort Study of Three-Vessel Disease

Total Bilirubin Predicts Severe Progression of Diabetic Retinopathy and the Possible Causal Mechanism

Development and Validation of Pretreatment Serum Total Bilirubin As a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study.

Bilirubin Levels as Potential Indicators of Disease Severity in Coronavirus Disease Patients: A Retrospective Cohort Study

Association Between Serum Total Bilirubin Level and Lung Function Decline in Patients with COPD: Results from a Pooled Study

Association Between Initial Serum Total Bilirubin and Clinical Outcome in Myocardial Infarction with Non-Obstructive Coronary Arteries

Associations of serum total bilirubin with survival outcomes in patients with cancer cachexia: A prospective, multicenter cohort study

Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis